The FDA overstepped its authority when it issued a rule last May to bring laboratory-developed tests under the agency’s ...

Vertex lost a legal battle against the federal government on Monday over its proposed fertility support program that would ...

Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients ...

As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of ...

FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...

A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...

LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...

Heart gene therapy maker Tenaya Therapeutics is laying off 30% to 40% of its staff by the end of the year, the company’s CEO Faraz Ali told Endpoints News by email.

SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...

BiomX's BX211 virus therapy shows promise in Phase 2 trial, reducing foot ulcer size in diabetic bone infection patients ...